Apellis to present positive Phase 2 NOBLE results of pegcetacoplan

Apellis Pharmaceuticals and Sobi announced that positive results from the Phase 2 NOBLE study investigating pegcetacoplan for the treatment of post-transplant recurrence of primary immune complex membranoproliferative glomerulonephritis, IC-MPGN, and C3 glomerulopathy will be presented at the American Society of Nephrology Kidney Week Annual Meeting. The results showed the potential for a treatment effect in both IC-MPGN and C3G patients treated with pegcetacoplan. At Week 12, of the 10 patients treated with pegcetacoplan: Eight patients showed a reduction in C3c staining by one or more orders of magnitude of intensity from baseline. Five patients showed a reduction in C3c staining by two or more orders of magnitude of intensity from baseline. Four patients showed zero staining intensity, indicating that C3c deposits were cleared. Excessive deposition of C3 breakdown products in the kidney leads to inflammation and damage of the kidney, often causing kidney failure. Additionally, in 12 weeks, treatment with pegcetacoplan showed a mean reduction of proteinuria, which is a key marker of disease progression1, in a subgroup of patients with high baseline levels). Other biomarkers also improved, including an increase in mean serum C3, reduction in mean sC5b-9, and stabilization of kidney function as measured by estimated glomerular filtration rate. There were no discontinuations due to treatment-emergent adverse events.